Identification of miRNA signature for predicting the prognostic biomarker of squamous cell lung carcinoma

Liu, Huanqing; Li, Tingting; Dong, Chunsheng; Lyu, Jun

doi:10.1371/journal.pone.0264645

Cited by 5 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs have been shown to exert complex effects on lung cancer development and progression, including regulation of cancer growth, angiogenesis and metastasis, domination of host immune responses and remodeling of the tumor microenvironment 53 – 56 . In recent years, miRNAs have been revealed as a valuable diagnostic biomarker of lung cancer and also a key factors for predicting the prognosis of disease 12 , 57 . In our study, we examined the potential for changes in miR-150 expression level in relation to the diagnostic practice.…”

Section: Discussionmentioning

confidence: 99%

Panel of miR-150 and linc00673, regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer

Baran

Kordiak

Jabłoński

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The C–C motif ligand 20 (CCL20) is a chemokine that specifically binds to the chemokine receptor 6 (CCR6) and the CCL20/CCR6 axis has been implicated in the non-small lung cancer (NSCLC) development and progression. Its expression is regulated by mutual interactions of non-coding RNAs (ncRNAs). This goals of presented study was to evaluate the expression level of CCR6/CCL20 mRNA in NSCLC tissue comparative to selected ncRNAs: miR-150, linc00673. The expression level of the studied ncRNAs was also assessed in serum extracellular vesicles (EVs). Thirty patients (n = 30) were enrolled as the study cohort. Total RNA was isolated from tumor tissue, adjacent macroscopically unchanged tissue and serum EVs. The expression level of studied genes and ncRNAs were estimated based on the qPCR method. Higher expression level of CCL20 mRNA but lower expression level of CCR6 mRNA were observed in tumor in comparison to control tissue. Relative to the smoking status, higher CCL20 (p < 0.05) and CCR6 mRNA (p > 0.05) expression levels were observed in current smokers than in never smokers. In serum EVs the expression level of miR-150 has a negative correlation with AJCC tumor staging, whereas the expression level of linc00673 positively correlated (p > 0.05). The lower expression level of miR-150 and higher expression level of linc00673 in serum EVs were observed in NSCLC patients with lymph nodes metastases (p > 0.05). Regarding the histopathological type, significantly lower expression level of miR-150 and higher expression level of linc00673 were observed in the serum EVs of patients with AC compared to patient with SCC. Our findings revealed that smoking significantly changed the expression level of CCL20 mRNA in NSCLC tissue. Changes in expression levels of miR-150 and linc00673 in the serum EVs of NSCLC patients in relation to presence of lymph node metastases and the stage of cancer development may serve as a non-invasive molecular biomarkers of tumor progression. Furthermore, expression levels of miR-150 and linc00673 may serve as non-intrusive diagnostic biomarkers differentiating adenocarcinoma from squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Panel of miR-150 and linc00673, regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer

Baran

Kordiak

Jabłoński

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…When most patients with advanced LUSC have experienced chemotherapy resistance and recurrence; and those same patients have had to endure the toxic side effects of chemotherapy, which considerably reduces the quality of life [ 6 ]. In-depth research on the treatment of LUSC mainly focused on the development of a clinical model of LUSC [ 7 ], the construction of markers for diagnosis and prognosis [ 8 , 9 ], and the optimization of the related diagnosis and treatment scheme [ 10 , 11 ]. Natural products and their derivatives as natural sources of anticancer drugs have great potential in the treatment of many tumors; however, there are still some gaps in the research on natural products in LUSC, and new molecular-targeting drugs may be beneficial in the treatment of LUSC [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

The Mechanism of Quercetin in the Treatment of Lung Squamous Cell Carcinoma Based on a Protein-Protein Interaction Network

Zhang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Lung squamous cell carcinoma (LUSC) is characterized by poor prognosis and obvious limitations of therapeutic methods. The molecular target and mechanism of quercetin (QR), a natural anticancer product with extensive pharmacological activities, on lung squamous cell carcinoma is still unclear. Method. The effects of QR on LUSC were examined using cell proliferation, migration, and invasion tests. Key target genes were screened using The Cancer Genome Atlas (TCGA) database, Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) database, STRING website, topology, and prognosis analysis, molecular docking, and other bioinformatics methods for further analysis. Finally, the effects of QR on the expression of key targets in LUSC cells were detected using a cell cycle assay and western blotting. Results. Our study demonstrates that QR not only inhibits the proliferation of LUSC but also affects the invasion and metastasis of LUSC. After downloading and analyzing the TCGA database, 2150 differentially expressed genes were identified. PLK1, CDC20, and BUB1B were identified using enrichment analysis, topological network analysis, cluster analysis, and molecular docking screening. Subsequent experiments showed that QR could interfere with the cell cycle and downregulate the expression of the target gene PLK1 at the protein level. Conclusions. We found that QR not only inhibits the proliferation, migration, and invasion but also blocks the cell cycle progression of LUSC. QR downregulated the expression of the LUSC target gene PLK1 at the protein level.

show abstract

Transcriptome profiling and metabolic pathway analysis towards reliable biomarker discovery in early-stage lung cancer

Thirunavukkarasu,

Ramesh,

Karuppasamy

et al. 2024

J Appl Genetics

View full text Add to dashboard Cite

Identification of miRNA signature for predicting the prognostic biomarker of squamous cell lung carcinoma

Cited by 5 publications

References 56 publications

Panel of miR-150 and linc00673, regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer

Panel of miR-150 and linc00673, regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer

The Mechanism of Quercetin in the Treatment of Lung Squamous Cell Carcinoma Based on a Protein-Protein Interaction Network

Transcriptome profiling and metabolic pathway analysis towards reliable biomarker discovery in early-stage lung cancer

Contact Info

Product

Resources

About